Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hypertrophic Cardiomyopathy
100%
Baseline Characteristics
100%
Angiotensin Receptor Blockers
60%
Mutation Carriers
40%
New York Heart Association Class
40%
Old Age
40%
New York Heart Association Functional Class
40%
Valsartan
40%
MYH7
40%
Sarcomeric mutations
40%
Disease Progression
20%
Placebo-controlled
20%
Advanced Disease
20%
Unique Identifier
20%
Clinical Trial Registry
20%
Genotype
20%
Nineteen
20%
Maximal Oxygen Uptake
20%
Left Ventricular Wall Thickness
20%
Normal Function
20%
Left Ventricular Hypertrophy
20%
Hypertrophic Obstructive Cardiomyopathy
20%
Functional Capacity
20%
Cardiac Magnetic Resonance
20%
Disease Manifestations
20%
Disease Evolution
20%
Late Gadolinium Enhancement
20%
Sarcomeric Gene mutation
20%
Class II mutations
20%
Medicine and Dentistry
Hypertrophic Cardiomyopathy
100%
New York Heart Association Class
66%
Angiotensin Receptor Antagonist
50%
Valsartan
33%
MYH7
33%
Diseases
33%
Oxygen Consumption
16%
Clinical Trial
16%
Placebo
16%
Gene Mutation
16%
Disease Exacerbation
16%
Disease Course
16%
Ventricular Hypertrophy
16%
Functional Status
16%
Left Ventricular Hypertrophy
16%
Cardiac Magnetic Resonance Imaging
16%
Gadolinium
16%
Biochemistry, Genetics and Molecular Biology
Angiotensin Receptor
100%
MYH7
66%
Clinical Trial
33%
Gene Mutation
33%
Oxygen Consumption
33%
Functional Status
33%
Genotyping
33%
Gadolinium
33%
Pharmacology, Toxicology and Pharmaceutical Science
Hypertrophic Cardiomyopathy
100%
Angiotensin Receptor Antagonist
50%
Valsartan
33%
Diseases
33%
Placebo
16%
Clinical Trial
16%
Disease Exacerbation
16%
Functional Status
16%
Disease Course
16%
Heart Left Ventricle Hypertrophy
16%
Heart Ventricle Hypertrophy
16%
Gadolinium
16%